Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity
Sialic acid-binding Immunoglobulin-like lectin-9 (Siglec-9) is a glyco-immune negative checkpoint expressed on several immune cells. Siglec-9 exerts its inhibitory effects by binding to sialoglycan ligands expressed on cancer cells, enabling them to evade immunosurveillance. We developed a panel of...
Guardado en:
Autores principales: | Hyeree Choi, Michelle Ho, Opeyemi S. Adeniji, Leila Giron, Devivasha Bordoloi, Abhijeet J. Kulkarni, Alfredo Perales Puchalt, Mohamed Abdel-Mohsen, Kar Muthumani |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c25bf30ad0a244629991b3e95285bea3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Siglecs as Therapeutic Targets in Cancer
por: Jackwee Lim, et al.
Publicado: (2021) -
Anti-Tumor Activity of Expanded PBMC-Derived NK Cells by Feeder-Free Protocol in Ovarian Cancer
por: Minhua Chen, et al.
Publicado: (2021) -
Siglec-7 May Limit Natural Killer Cell–mediated Antitumor responses in Bladder Cancer Patients
por: Sulayman Benmerzoug, et al.
Publicado: (2021) -
Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Sergey Kulemzin, et al.
Publicado: (2021) -
ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell Function
por: Silvia D’Amico, et al.
Publicado: (2021)